Title: Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.
Journal: The Lancet. Oncology 20121101
Title: Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks.
Journal: Chinese journal of cancer 20120801
Title: Sapacitabine for cancer.
Journal: Expert opinion on investigational drugs 20120401
Title: Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine.
Journal: Expert opinion on investigational drugs 20120401
Title: Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.
Journal: Seminars in oncology 20111001
Title: Applicability of a 'Pick a Winner' trial design to acute myeloid leukemia.
Journal: Blood 20110901
Title: Novel agents for the treatment of acute myeloid leukemia in the older patient.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN 20110301
Title: Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.
Journal: Current medicinal chemistry 20110101
Title: Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types.
Journal: British journal of cancer 20101026
Title: Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100110
Title: Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia.
Journal: Current opinion in hematology 20080301
Title: Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.
Journal: British journal of cancer 20070828
Title: A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies.
Journal: Investigational new drugs 20061101
Title: A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors.
Journal: Investigational new drugs 20060701
Title: Drug evaluation: sapacitabine--an orally available antimetabolite in the treatment of cancer.
Journal: Current opinion in investigational drugs (London, England : 2000) 20060601
Title: Survival efficacy of adjuvant cytosine-analogue CS-682 in a fluorescent orthotopic model of human pancreatic cancer.
Journal: Cancer research 20040301
Title: Selective antimetastatic activity of cytosine analog CS-682 in a red fluorescent protein orthotopic model of pancreatic cancer.
Journal: Cancer research 20030901
Title: High-resolution magnetic resonance imaging of the efficacy of the cytosine analogue 1-[2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl]-N(4)-palmitoyl cytosine (CS-682) in a liver-metastasis athymic nude mouse model.
Journal: Cancer research 20030515
Title: Serova M, et al. Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells. Br J Cancer. 2007 Sep 3;97(5):628-36.
Title: Green SR, et al. Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types. Br J Cancer. 2010 Oct 26;103(9):1391-9.
